MX2020011377A - Metodos y composiciones para el tratamiento de urticaria cronica. - Google Patents
Metodos y composiciones para el tratamiento de urticaria cronica.Info
- Publication number
- MX2020011377A MX2020011377A MX2020011377A MX2020011377A MX2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A
- Authority
- MX
- Mexico
- Prior art keywords
- chronic urticaria
- compositions
- methods
- treating chronic
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
La presente invención proporciona métodos para el tratamiento de la urticaria crónica. En particular, la presente invención proporciona métodos para el tratamiento de la urticaria crónica mediante la administración de anticuerpos que se unen a Siglec-8 humano o composiciones que comprenden los anticuerpos. La presente invención también proporciona artículos de manufactura o kits que comprenden anticuerpos que se unen a Siglec-8 humano para el tratamiento de la urticaria crónica.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862667242P | 2018-05-04 | 2018-05-04 | |
US201962788719P | 2019-01-04 | 2019-01-04 | |
US201962797817P | 2019-01-28 | 2019-01-28 | |
US201962803211P | 2019-02-08 | 2019-02-08 | |
US201962806657P | 2019-02-15 | 2019-02-15 | |
PCT/US2019/030523 WO2019213468A1 (en) | 2018-05-04 | 2019-05-03 | Methods and compositions for treating chronic urticaria |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011377A true MX2020011377A (es) | 2020-11-24 |
Family
ID=68386174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011377A MX2020011377A (es) | 2018-05-04 | 2019-05-03 | Metodos y composiciones para el tratamiento de urticaria cronica. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210246205A1 (es) |
EP (1) | EP3788078A4 (es) |
JP (2) | JP2021523117A (es) |
KR (1) | KR20210005245A (es) |
CN (1) | CN112384535A (es) |
AU (1) | AU2019262167A1 (es) |
BR (1) | BR112020022236A2 (es) |
CA (1) | CA3099338A1 (es) |
MX (1) | MX2020011377A (es) |
SG (1) | SG11202010911WA (es) |
WO (1) | WO2019213468A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019022912A2 (pt) | 2017-05-05 | 2020-05-26 | Allakos Inc. | Métodos e composições para tratar doenças oculares alérgicas |
US20230250191A1 (en) * | 2020-07-10 | 2023-08-10 | Shanghai Jemincare Pharmaceutical Co., Ltd. | Anti-ige engineered antibody and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201603127WA (en) * | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
KR20230107382A (ko) * | 2013-12-09 | 2023-07-14 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
US10183996B2 (en) * | 2014-02-28 | 2019-01-22 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
-
2019
- 2019-05-03 US US17/051,766 patent/US20210246205A1/en active Pending
- 2019-05-03 EP EP19796049.5A patent/EP3788078A4/en active Pending
- 2019-05-03 WO PCT/US2019/030523 patent/WO2019213468A1/en active Application Filing
- 2019-05-03 SG SG11202010911WA patent/SG11202010911WA/en unknown
- 2019-05-03 BR BR112020022236-4A patent/BR112020022236A2/pt unknown
- 2019-05-03 CA CA3099338A patent/CA3099338A1/en active Pending
- 2019-05-03 MX MX2020011377A patent/MX2020011377A/es unknown
- 2019-05-03 KR KR1020207034828A patent/KR20210005245A/ko unknown
- 2019-05-03 CN CN201980044867.8A patent/CN112384535A/zh active Pending
- 2019-05-03 JP JP2020561727A patent/JP2021523117A/ja not_active Withdrawn
- 2019-05-03 AU AU2019262167A patent/AU2019262167A1/en active Pending
-
2024
- 2024-02-19 JP JP2024022749A patent/JP2024045612A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3099338A1 (en) | 2019-11-07 |
JP2024045612A (ja) | 2024-04-02 |
EP3788078A4 (en) | 2022-03-02 |
JP2021523117A (ja) | 2021-09-02 |
BR112020022236A2 (pt) | 2021-02-02 |
SG11202010911WA (en) | 2020-12-30 |
CN112384535A (zh) | 2021-02-19 |
KR20210005245A (ko) | 2021-01-13 |
WO2019213468A1 (en) | 2019-11-07 |
AU2019262167A1 (en) | 2020-12-10 |
EP3788078A1 (en) | 2021-03-10 |
US20210246205A1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
PH12018500642A1 (en) | Anti-garp antibody | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
EP3964527A3 (en) | Combination therapy for cancer | |
PH12020552229A1 (en) | Il-11ra antibodies | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
JOP20190285A1 (ar) | استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد | |
WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. |